NEWS

September 8, 2020
Outlook Therapeutics to Present at Two Upcoming Investor Conferences
More
Interview with Proactive Investors
Outlook Therapeutics’ wet AMD therapy study results validates expectations, looks forward to Phase 3
Link to Video

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

ABOUT ONS-5010

ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity.

ONS-5010 is currently being evaluated in our Phase 3 program for wet AMD and is expected to be filed with the FDA as a new BLA for this ophthalmic indication. Outlook Therapeutics also intends to commence additional clinical trials for ONS-5010 in DME and BRVO. The INN for ONS-5010 is bevacizumab-vikg.

If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab to treat retinal diseases.